Willow Biosciences Forecasts Revenue Surge, Expands Partnerships
Company Announcements

Willow Biosciences Forecasts Revenue Surge, Expands Partnerships

Willow Biosciences Inc (TSE:WLLW) has released an update.

Willow Biosciences Inc. announces a strategic partnership with Laurus Labs for the development and manufacturing of active pharmaceutical ingredients, forecasting significant revenue growth with over $1 million expected in Q2 and more than $3.5 million in 2024. The company is also expanding its technological capabilities with the appointment of AI and industry experts Dr. Richard Fox and Mr. Gregory Rocklin, and adding a new program in the burgeoning biopesticide market. Additionally, Willow has secured its first patent and plans to file five more in 2024, focusing on steroid production technology.

For further insights into TSE:WLLW stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskWillow Biosciences Launches New Enzyme Development Program
TipRanks Canadian Auto-Generated NewsdeskWillow Biosciences Strikes Key Deal with Kalsec Inc.
TipRanks Canadian Auto-Generated NewsdeskWillow Biosciences Soars with Revenue Growth and Strategic Partnerships
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App